首页> 外文期刊>日本東洋医学雑志 >Inhibitory Effect of Kampo (Japanese Traditional Herbal Medicine) Therapy on the Development of Hepatocellular Carcinoma in Patients with HCV-related Chronic Hepatic Disease Usefulness of Kampo Therapy based on Traditional Theory
【24h】

Inhibitory Effect of Kampo (Japanese Traditional Herbal Medicine) Therapy on the Development of Hepatocellular Carcinoma in Patients with HCV-related Chronic Hepatic Disease Usefulness of Kampo Therapy based on Traditional Theory

机译:日本传统草药对中国丙型肝炎病毒相关的慢性肝病患者肝细胞癌的抑制作用传统理论对日本草药的治疗作用

获取原文
获取原文并翻译 | 示例
       

摘要

We evaluated the effect of Kampo therapy in which Kampo formulae were selected based on Japanese traditional theory, on the development of hepatocellular carcinoma (HCC) in patients with hepatitis C virus (HCV)-related chronic liver disease. One hundred forty HCV-infected outpatients without HCC at their first examination and who were observed for more than one year, were included. The patients were divided into three groups according to the initial platelet count (P1t) : P1t less than 10 x 10/muL (Group I), P1t between 10 x10~4/muLL and 14 x 10~4/muL (Group II), and Pit greater than 14 x 10~4/muL (Group III). For each patient, Kampo formulae were selected according to the patient's symptoms and physical findings at each clinic visit. The incidence of HCC calculated by the person-years method, was 0.89% in Group I. 1.55% in Group II and 0.29% in Group III. The annual incidence of HCC among our patients was low compared with that among untreated patients in previous reports. In addition, the incidence of HCC among our patients was low comp'ared with that of previous studies where Shosaikoto or Juzentaihoto was administered for a long period of time. In the present study, age over 60 years was a possible risk factor for HCC. However, sex and patterns of the change in alanine aminotransferase level (ALT) wereall patients, with Hochuekkito being the most frequent. These results suggest that Kampo treatment in whic not associated with the development of HCC. A total of 53 different Kampo formulae were prescribed, for h Kampo formulae are selected based on traditional theory, may be more useful than treatment by a single Kampo formula for preventing the development of HCC in patients with HCV-related chronic liver disease.
机译:我们评估了基于日​​本传统理论选择了汉方配方的汉方疗法对与丙型肝炎病毒(HCV)相关的慢性肝病患者肝细胞癌(HCC)发展的影响。包括一百四十例首次被检查且没有被观察到超过一年的HCV感染门诊患者。根据初始血小板计数(P1t)将患者分为三组:P1t小于10 x 10 /μL(I组),P1t在10 x10〜4 /μL与14 x 10〜4 /μL之间(II组) ,并且坑大于14 x 10〜4 /μL(第III组)。对于每位患者,根据每次临床就诊时患者的症状和体格检查结果选择Kampo配方。通过人年法计算的肝癌发生率在第一组为0.89%,第二组为1.55%,第三组为0.29%。在以前的报告中,与未经治疗的患者相比,我们患者的HCC年发生率较低。此外,与长期服用Shosaikoto或Juzentaihoto的先前研究相比,我们患者中的HCC发生率较低。在本研究中,年龄超过60岁是肝癌的可能危险因素。然而,所有患者的性别和丙氨酸氨基转移酶水平(ALT)改变的模式均以Hochuekkito为最常见。这些结果表明,Kampo治疗与肝癌的发生无关。总共规定了53种不同的Kampo配方,因为h的Kampo配方是根据传统理论选择的,可能比单一的Kampo配方治疗对预防HCV相关的慢性肝病患者HCC的发展更有用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号